# Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

> **NCT01670877** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 56 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Fulvestrant
- **DRUG:** Trastuzumab
- **PROCEDURE:** Tumor biopsy
- **PROCEDURE:** Research blood sample

## Key facts

- **NCT ID:** NCT01670877
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-11
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-03-11
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670877, "Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01670877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*